TenNor’s class I new drug, TNP-2198 capsule, has been approved by CDE for the initiation of clinical studies. This is TenNor’s another new pharmaceutical product entering clinical stage after TNP-2092 IV and TNP-2092 PO. TNP-2198 developed by TenNor is a novel and highly-differentiated antibiotic product, aiming at solving the major unmet clinical needs in the treatment of anaerobic and micro-aerobic bacterial infections.

TNP-2198 is a multi-targeting new antimicrobial drug with global intellectual properties. It has unique antimicrobial activity against anaerobes and micro-aerobic bacteria. The infections caused by the anaerobic and micro-aerobic bacterial are closely associated with many common and major diseases. Nowadays, the choice of treatment for those diseases are very limited, mainly relying on drugs such as nitroimidazoles, which have been on the market for decades. The drug resistance has caused serious problems, which lead to high recurrence rate and low cure rate of the diseases. It is an urgent need for antibiotics with novel mechanism of actions. However, the pipeline of new antibiotics in global development against anaerobic and micro-aerobic bacterial infections is very weak. With unique multi-targeting and synergistic features, TNP-2198 has demonstrated good activity against clinical isolates, including drug-resistant bacterial strains. In comparing with existing anti-infective agents, TNP-2198 has the potential advantages in the treatment of Helicobacter pylori infection, bacterial vaginosis and Clostridium difficile infections.

‘This IND application was based on extensive preclinical studies’, said Xiangyi Xu, Director of Regulatory Affairs in TenNor, ‘Successful development of TNP-2198 will address important unmet needs in the field of anti-infections and we are expecting it to become a new therapeutic choice for anaerobic and micro-aerobic bacterial infections.’

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of January 24, 2026, TenNor Therapeutics had built a pipeline of seven innovative programs, including two Core Products, namely, rifasutenizol (TNP-2198), a new molecular entity (“NME”) drug candidate used as part of a triple therapy in combination with amoxicillin and a proton pump inhibitor for the treatment of Helicobacter pylori (“H. pylori”) infection in China and U.S. as well as monotherapy for bacterial vaginosis and C. difficile infection in China; and rifaquizinone (TNP-2092 injection), a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections, i.e. acute bacterial skin and skin structure infection (“ABSSSI”) and prosthetic joint infection (“PJI”), as well as left ventricular assist device infection (“LVADI”) and catheter-related bloodstream infection (“CRBSI”) in China and the U.S.

For more information, please visit: www.tennortherapeutics.com